FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568000269> ?p ?o ?g. }

• W2568000269 endingPage "S6" @default.
• W2568000269 startingPage "S6" @default.
• W2568000269 abstract "Non-small cell lung cancer (NSCLC) with brain metastases (M) had a poor prognosis. Whole brain irradiation (WBI) is a standard of care for this critical medical condition. The median survival is only 4-6 months. Small molecule inhibitors of epidermal growth factor receptor (EGFR) including icotinib achieved very successful results in advanced NSCLC with EGFR mutations. There were no prospective randomized clinical trials to explore the efficacy of EGFR tyrosine kinase inhibitors (TKIs) on brain M. Advanced NSCLC with EGFR sensitive mutations and brain M were randomized to WBI plus chemotherapy (chemo) or icotinib. Patients in WBI arm received radiotherapy with 30Gy/3Gy/10 fractions plus concurrent or sequential doublet chemo of 4-6 cycles. Patients in EGFR TKI arm received icotinib 125mg orally tid until disease progression. Icotinib could be continued beyond progression if clinical benefit was observed by the investigator. Crossover to icotinib from WBI could be permitted. Key inclusion criteria were EGFR mutations and radiologically confirmed brain M with at least 3 lesions. The primary endpoint was intracranial progression-free survival (iPFS) by investigator assessments according to RECIST v1.1. The secondary endpoints included objective response rate (ORR), PFS and overall survival (OS). Safety and tolerability were assessed by measuring adverse events (AEs)(CTCAE v4). From Dec. 2012 to June 2015, 176 patients from 17 sites were randomized to WBI+Chemo arm (N=91) or icotinib arm (N=85). The baseline clinicopathologic factors were balanced between the two groups. Median age was 58, PS 1 was 87.2%, non-smoker 70.9%, adenocarcinoma 96.8%, symptomatic brain M were 16.5%. Icotinib significantly improved median iPFS compared with WBI+chemo: hazard ratio [HR] 0.56; 95% CI: 0.36-0.90; p=0.014 (10.0 vs 4.8 months). Median PFS was 6.8 vs 3.4 months, (HR 0.44, 95% CI 0.31-0.63, P<0.001). Median OS had no significant difference between the arms (18.0 vs 20.5 months, HR 0.93, 95%CI 0.60-1.44, P=0.734). Intracranial ORR was significantly improved with icotinib than WBI+Chemo (67.1% vs 40.9%; p<0.001); Overall ORR was 55.0% vs 11.1% (P<0.001). Grade ≥3 AEs assessed by the investigators were reported in 8.2% (N=7) of patients treated with icotinib and 26.2% (N=28) treated with WBI+Chemo. Most common causally related AEs in the icotinib arm were increased liver transaminase & rash; in the WBI+Chemo arm were hematologic toxicity. Icotinib demonstrated superior iPFS, PFS and ORR over WBI+Chemo in EGFR mutant advanced NSCLC with brain M, and well-tolerated safety profile. Icotinib would be a treatment option for EGFR mutant patients with brain M (NCT01724801)." @default.
• W2568000269 created "2017-01-13" @default.
• W2568000269 creator A5002096737 @default.
• W2568000269 creator A5004598929 @default.
• W2568000269 creator A5004928583 @default.
• W2568000269 creator A5016003597 @default.
• W2568000269 creator A5024628268 @default.
• W2568000269 creator A5029267850 @default.
• W2568000269 creator A5032952436 @default.
• W2568000269 creator A5046162972 @default.
• W2568000269 creator A5052876946 @default.
• W2568000269 creator A5056497965 @default.
• W2568000269 creator A5063300954 @default.
• W2568000269 creator A5066716873 @default.
• W2568000269 creator A5067152089 @default.
• W2568000269 creator A5074092905 @default.
• W2568000269 creator A5075302079 @default.
• W2568000269 creator A5078402710 @default.
• W2568000269 date "2017-01-01" @default.
• W2568000269 modified "2023-10-17" @default.
• W2568000269 title "PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)" @default.
• W2568000269 doi "https://doi.org/10.1016/j.jtho.2016.11.007" @default.
• W2568000269 hasPublicationYear "2017" @default.
• W2568000269 type Work @default.
• W2568000269 sameAs 2568000269 @default.
• W2568000269 citedByCount "15" @default.
• W2568000269 countsByYear W25680002692017 @default.
• W2568000269 countsByYear W25680002692018 @default.
• W2568000269 countsByYear W25680002692019 @default.
• W2568000269 countsByYear W25680002692020 @default.
• W2568000269 countsByYear W25680002692021 @default.
• W2568000269 countsByYear W25680002692023 @default.
• W2568000269 crossrefType "journal-article" @default.
• W2568000269 hasAuthorship W2568000269A5002096737 @default.
• W2568000269 hasAuthorship W2568000269A5004598929 @default.
• W2568000269 hasAuthorship W2568000269A5004928583 @default.
• W2568000269 hasAuthorship W2568000269A5016003597 @default.
• W2568000269 hasAuthorship W2568000269A5024628268 @default.
• W2568000269 hasAuthorship W2568000269A5029267850 @default.
• W2568000269 hasAuthorship W2568000269A5032952436 @default.
• W2568000269 hasAuthorship W2568000269A5046162972 @default.
• W2568000269 hasAuthorship W2568000269A5052876946 @default.
• W2568000269 hasAuthorship W2568000269A5056497965 @default.
• W2568000269 hasAuthorship W2568000269A5063300954 @default.
• W2568000269 hasAuthorship W2568000269A5066716873 @default.
• W2568000269 hasAuthorship W2568000269A5067152089 @default.
• W2568000269 hasAuthorship W2568000269A5074092905 @default.
• W2568000269 hasAuthorship W2568000269A5075302079 @default.
• W2568000269 hasAuthorship W2568000269A5078402710 @default.
• W2568000269 hasBestOaLocation W25680002691 @default.
• W2568000269 hasConcept C121608353 @default.
• W2568000269 hasConcept C126322002 @default.
• W2568000269 hasConcept C143998085 @default.
• W2568000269 hasConcept C168563851 @default.
• W2568000269 hasConcept C197934379 @default.
• W2568000269 hasConcept C203092338 @default.
• W2568000269 hasConcept C2776256026 @default.
• W2568000269 hasConcept C2776694085 @default.
• W2568000269 hasConcept C2778164965 @default.
• W2568000269 hasConcept C2778375690 @default.
• W2568000269 hasConcept C2779013556 @default.
• W2568000269 hasConcept C2779438470 @default.
• W2568000269 hasConcept C71924100 @default.
• W2568000269 hasConceptScore W2568000269C121608353 @default.
• W2568000269 hasConceptScore W2568000269C126322002 @default.
• W2568000269 hasConceptScore W2568000269C143998085 @default.
• W2568000269 hasConceptScore W2568000269C168563851 @default.
• W2568000269 hasConceptScore W2568000269C197934379 @default.
• W2568000269 hasConceptScore W2568000269C203092338 @default.
• W2568000269 hasConceptScore W2568000269C2776256026 @default.
• W2568000269 hasConceptScore W2568000269C2776694085 @default.
• W2568000269 hasConceptScore W2568000269C2778164965 @default.
• W2568000269 hasConceptScore W2568000269C2778375690 @default.
• W2568000269 hasConceptScore W2568000269C2779013556 @default.
• W2568000269 hasConceptScore W2568000269C2779438470 @default.
• W2568000269 hasConceptScore W2568000269C71924100 @default.
• W2568000269 hasIssue "1" @default.
• W2568000269 hasLocation W25680002691 @default.
• W2568000269 hasOpenAccess W2568000269 @default.
• W2568000269 hasPrimaryLocation W25680002691 @default.
• W2568000269 hasRelatedWork W1990197915 @default.
• W2568000269 hasRelatedWork W2044653442 @default.
• W2568000269 hasRelatedWork W2062839819 @default.
• W2568000269 hasRelatedWork W2087016115 @default.
• W2568000269 hasRelatedWork W2305775430 @default.
• W2568000269 hasRelatedWork W2427186628 @default.
• W2568000269 hasRelatedWork W2465571689 @default.
• W2568000269 hasRelatedWork W3024742273 @default.
• W2568000269 hasRelatedWork W3191427281 @default.
• W2568000269 hasRelatedWork W4311628015 @default.
• W2568000269 hasVolume "12" @default.
• W2568000269 isParatext "false" @default.
• W2568000269 isRetracted "false" @default.
• W2568000269 magId "2568000269" @default.
• W2568000269 workType "article" @default.